Who May Benefit?

Patient dissatisfaction is underreported—
96% of survey patients said they were dissatisfied with at least one aspect of their migraine treatment3*

Lasting Concerns


38% of survey patients reported lack of sustained relief 24 hours postdose.3*

Do you have patients who:

  • Get some relief from migraine symptoms with oral treatments, but pain comes back within 24 hours?4
  • Worry a migraine attack will come back when they need to be “on”?2,4

TRUDHESA™ HAS BEEN REPORTED TO PROVIDE SUSTAINED PAIN FREEDOM FOR UP TO 48 HOURS WITH A SINGLE DOSE.5†

Actor portrayal

*In a survey of 3930 US adults with migraine who reported use of oral acute prescription medication.3
Exploratory end points and post hoc analyses of patient-reported efficacy data in patients with migraine.6

Hit or Miss


55% of survey patients continued to have moderate to severe disability3*

Do you have patients who:

  • Get relief from their oral medication sometimes but not every time?7-9
  • Sometimes may miss taking their oral medication within the required dosing timeframe?13

TRUDHESA HAS BEEN REPORTED TO RELIABLY DELIVER CONSISTENT RELIEF — EVEN WHEN TAKEN LATE INTO A MIGRAINE ATTACK.14†

Actor portrayal

*In a survey of 3930 US adults with migraine who reported use of oral acute prescription medication.3
Exploratory end points and post hoc analyses of patient-reported efficacy data in patients with migraine.14

Rapid-Onset Prone


65% of survey patients reported lack of relief from a rapid-onset migraine attack3*

Do you have patients who:

  • Experience sudden, unpredictable migraine attacks?2,4
  • Often experience migraine attacks accompanied by nausea, which delays or prevents taking oral treatment?3,10

WITH A RESPONSE TIME OF 15 MINUTES IN SOME PATIENTS, TRUDHESA HAS BEEN REPORTED TO OFFER RAPID PAIN FREEDOM.2†

Actor portrayal

*In a survey of 3930 US adults with migraine who reported use of oral acute prescription medication.3
Exploratory end points and post hoc analyses of patient-reported efficacy data in patients with migraine.5

When Breakthrough Migraine Attacks Still Occur


Preventive treatments may reduce attack frequency but breakthroughs still occur7-9

Do you have patients who:

  • Are taking a preventive treatment and have tried oral acute medications for migraine without getting complete relief?4,8,15

TRUDHESA IS AN ACUTE TREATMENT FOR MIGRAINE THAT CAN PROVIDE RELIEF WITH NO DOSING WINDOW.14†

Actor portrayal

Exploratory end points and post hoc analyses of patient-reported efficacy data in patients with migraine.6

Actor portrayal

70% OF PATIENTS SAID THEY WOULD NOT TURN DOWN ANY ROUTE OF ADMINISTRATION RECOMMENDED BY THEIR HEALTHCARE PROVIDER.16‡

‡Survey conducted in May 2021 with 500 patients through Focus Vision as a way to gather additional insights about patients diagnosed with migraine and their attitudes towards migraine medications. This survey was not Institutional Review Board (IRB) approved.

Be Direct.

It may help them get the relief they need.

Consider asking your patients these questions to see if they may be right for Trudhesa:

  • “Does a single dose of your current medication give you the migraine symptom relief you need for at least 24 hours?”5
  • “Do you feel like you can rely on your current acute medication to work when you need it to?”5,7-9
  • “Do you ever have any stomach issues or nausea when you’re having a migraine attack?”10,11
  • “Are you always able to take your migraine pill or dissolving tablet early enough for it to work?”2,12

Coverage and Savings

References: 1. Hoekman J, Ray S, Aurora SK, Shrewsbury SB. The upper nasal space—a novel delivery route ideal for central nervous system drugs. US Neurology. 2020;16(1):25-31. 2. Data on File. Impel NeuroPharma. 2020. 3. Lipton RB, Munjal S, Buse DC, et al. Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019;59(8):1310-1323. 4. Smith TR, Aurora S, Hocevar-Trnka J, Shrewsbury S. Acute treatment of migraine with INP104: exploratory efficacy from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 5. Tepper SJ, Ailani J, Shrewsbury SB, Aurora SK. Recurrence rates for INP104 for the acute treatment of migraine: results from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 6. Lipton RB, Nye BL, Hirman J, Shrewsbury SB, Aurora SK. Treatment consistency across multiple migraine attacks: results from the phase 3 open-label STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 7. Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) – then and now: a narrative review. Headache. 2020;60(1):40-57. 8. Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. Headache. 2014;54(2):278-289. 9. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44(7):661-668. 10. Aurora SK, Papapetropoulos, Kori S. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implication. Cephalalgia. 2013;33(6):408-415. 11. Trudhesa. Prescribing information. Impel NeuroPharma; 2021. 12. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 13. Ng-Mak DS, Hu XH, Chen Y, Ma L, Solomon G. Time to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. Inter J Clin Prac. 2007;61(7):1091-111. 14. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients [published online ahead of print, 2021 Aug 7]. Headache. 2021;10.1111/head.14184. doi:10.1111/head.14184. 15. Géraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376-388. 16. Data on File. Patient survey results. 2021.